OPKO Health Inc. (OPK) announced Friday morning that its Phase 3 study of hGH-CTP in adults with growth hormone deficiency demonstrated no statistical difference versus placebo on the study's primary endpoint.
from RTT - Before the Bell http://ift.tt/2iKzf1f
via IFTTT
No comments:
Post a Comment